vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and HEALTHY CHOICE WELLNESS CORP. (HCWC). Click either name above to swap in a different company.
HEALTHY CHOICE WELLNESS CORP. is the larger business by last-quarter revenue ($18.7M vs $10.7M, roughly 1.7× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -8.9%, a 32.4% gap on every dollar of revenue.
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
ABUS vs HCWC — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $18.7M |
| Net Profit | $2.5M | $-1.7M |
| Gross Margin | — | 39.1% |
| Operating Margin | 13.9% | -7.6% |
| Net Margin | 23.5% | -8.9% |
| Revenue YoY | 522.2% | — |
| Net Profit YoY | 112.7% | — |
| EPS (diluted) | $0.01 | $-0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $18.7M | ||
| Q3 25 | — | $19.0M | ||
| Q2 25 | $10.7M | $20.2M | ||
| Q1 25 | — | $20.3M | ||
| Q3 24 | — | $18.2M | ||
| Q4 23 | $2.1M | — | ||
| Q3 23 | $4.7M | — | ||
| Q2 23 | $4.7M | — |
| Q4 25 | — | $-1.7M | ||
| Q3 25 | — | $-1.2M | ||
| Q2 25 | $2.5M | $-339.4K | ||
| Q1 25 | — | $-712.4K | ||
| Q3 24 | — | $-2.7M | ||
| Q4 23 | — | — | ||
| Q3 23 | $-20.1M | — | ||
| Q2 23 | $-17.1M | — |
| Q4 25 | — | 39.1% | ||
| Q3 25 | — | 38.8% | ||
| Q2 25 | — | 40.1% | ||
| Q1 25 | — | 38.8% | ||
| Q3 24 | — | 38.4% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | -7.6% | ||
| Q3 25 | — | -3.2% | ||
| Q2 25 | 13.9% | -0.2% | ||
| Q1 25 | — | -2.0% | ||
| Q3 24 | — | -2.0% | ||
| Q4 23 | -967.2% | — | ||
| Q3 23 | -462.8% | — | ||
| Q2 23 | -395.3% | — |
| Q4 25 | — | -8.9% | ||
| Q3 25 | — | -6.4% | ||
| Q2 25 | 23.5% | -1.7% | ||
| Q1 25 | — | -3.5% | ||
| Q3 24 | — | -14.6% | ||
| Q4 23 | — | — | ||
| Q3 23 | -431.6% | — | ||
| Q2 23 | -367.5% | — |
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | $0.01 | $-0.03 | ||
| Q1 25 | — | $-0.07 | ||
| Q3 24 | — | $-0.29 | ||
| Q4 23 | $-0.12 | — | ||
| Q3 23 | $-0.12 | — | ||
| Q2 23 | $-0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $3.0M |
| Total DebtLower is stronger | $0 | $7.3M |
| Stockholders' EquityBook value | $83.0M | $7.3M |
| Total Assets | $103.3M | $33.5M |
| Debt / EquityLower = less leverage | 0.00× | 1.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $3.0M | ||
| Q3 25 | — | $3.0M | ||
| Q2 25 | $37.4M | $4.7M | ||
| Q1 25 | — | $1.8M | ||
| Q3 24 | — | $1.8M | ||
| Q4 23 | $126.0M | — | ||
| Q3 23 | $17.5M | — | ||
| Q2 23 | $27.2M | — |
| Q4 25 | — | $7.3M | ||
| Q3 25 | — | $8.5M | ||
| Q2 25 | $0 | $9.7M | ||
| Q1 25 | — | $10.6M | ||
| Q3 24 | — | $11.6M | ||
| Q4 23 | $0 | — | ||
| Q3 23 | $0 | — | ||
| Q2 23 | $0 | — |
| Q4 25 | — | $7.3M | ||
| Q3 25 | — | $5.9M | ||
| Q2 25 | $83.0M | $5.8M | ||
| Q1 25 | — | $2.1M | ||
| Q3 24 | — | $2.9M | ||
| Q4 23 | $106.0M | — | ||
| Q3 23 | $119.3M | — | ||
| Q2 23 | $134.7M | — |
| Q4 25 | — | $33.5M | ||
| Q3 25 | — | $33.7M | ||
| Q2 25 | $103.3M | $36.4M | ||
| Q1 25 | — | $34.1M | ||
| Q3 24 | — | $33.2M | ||
| Q4 23 | $144.4M | — | ||
| Q3 23 | $158.6M | — | ||
| Q2 23 | $176.8M | — |
| Q4 25 | — | 1.00× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | 0.00× | 1.69× | ||
| Q1 25 | — | 5.01× | ||
| Q3 24 | — | 3.95× | ||
| Q4 23 | 0.00× | — | ||
| Q3 23 | 0.00× | — | ||
| Q2 23 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-855.1K |
| Free Cash FlowOCF − Capex | — | $-927.1K |
| FCF MarginFCF / Revenue | — | -5.0% |
| Capex IntensityCapex / Revenue | 0.0% | 0.4% |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $675.4K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-855.1K | ||
| Q3 25 | — | $-308.7K | ||
| Q2 25 | $-15.7M | $1.1M | ||
| Q1 25 | — | $1.1M | ||
| Q3 24 | — | — | ||
| Q4 23 | $-17.3M | — | ||
| Q3 23 | $-21.8M | — | ||
| Q2 23 | $-19.6M | — |
| Q4 25 | — | $-927.1K | ||
| Q3 25 | — | $-351.3K | ||
| Q2 25 | — | $988.6K | ||
| Q1 25 | — | $965.3K | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | $-21.8M | — | ||
| Q2 23 | $-20.4M | — |
| Q4 25 | — | -5.0% | ||
| Q3 25 | — | -1.8% | ||
| Q2 25 | — | 4.9% | ||
| Q1 25 | — | 4.8% | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -468.4% | — | ||
| Q2 23 | -439.0% | — |
| Q4 25 | — | 0.4% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | — | 0.6% | ||
| Q3 24 | — | — | ||
| Q4 23 | 0.0% | — | ||
| Q3 23 | 0.7% | — | ||
| Q2 23 | 18.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
HCWC
| Retail Grocery | $17.1M | 91% |
| Food Service Restaurant | $1.7M | 9% |
